Carboxyamidotriazole Orotate
Modify Date: 2024-01-12 19:41:22
Carboxyamidotriazole Orotate structure
|
Common Name | Carboxyamidotriazole Orotate | ||
|---|---|---|---|---|
| CAS Number | 187739-60-2 | Molecular Weight | 580.765 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H16Cl3N7O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Carboxyamidotriazole OrotateCarboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor. Carboxyamidotriazole Orotate is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole Orotate shows anti-tumor, anti-inflammatory and antiangiogenic effects[1][2]. |
| Name | 776C212QQH |
|---|---|
| Synonym | More Synonyms |
| Description | Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor. Carboxyamidotriazole Orotate is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole Orotate shows anti-tumor, anti-inflammatory and antiangiogenic effects[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Carboxyamidotriazole Orotate (0.1-10 µM; 24-96 hours) inhibits cell proliferation of LAMA84R and K562R cell lines[1]. Carboxyamidotriazole Orotate inhibits the phosphorylation of a selected target of Bcr-Abl kinase. Tyrosine phosphorylation of CrkL is reduced by 5 µM Carboxyamidotriazole Orotate treatment[1]. Cell Viability Assay[1] Cell Line: LAMA84R and K562R cell lines Concentration: 0.1, 1, 5, 10 µM Incubation Time: 24, 48, 72, 96 hours Result: Showed a 50% growth reduction of the chronic myelogenous leukaemia (CML) lines with 5 µM CTO at 96 h time point. Western Blot Analysis[1] Cell Line: LAMA84R and K562R cell lines Concentration: 0.1, 1, 5 µM Incubation Time: 72 and 96 hours Result: A dose-dependent inhibition of both total and phosphorylated Bcr-Abl levels. |
| In Vivo | Carboxyamidotriazole Orotate (342, 513 mg/kg; i.p.; Q1D×5 for two rounds) displays antitumor activity on CML xenografts[1]. Animal Model: Male NOD/SCID mice four-to-five week old[1] Dosage: 342, 513 mg/kg Administration: i.p.; Q1D×5 for two rounds Result: Increase survival. |
| References |
| Molecular Formula | C22H16Cl3N7O6 |
|---|---|
| Molecular Weight | 580.765 |
| Exact Mass | 579.022766 |
| Hazard Codes | Xi |
|---|
| 2,6-Dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylic acid - 5-amino-1-[3,5-dichloro-4-(4-chlorobenzoyl)benzyl]-1H-1,2,3-triazole-4-carboxamide (1:1) |
| 4-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-, compd. with 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-1H-1,2,3-triazole-4-carboxamide (1:1) |
| 776C212QQH |